Heartflow (NASDAQ:HTFL) Stock Sees Heavy Put Option Buying

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) was the target of some unusual options trading on Friday. Investors acquired 6,628 put options on the company. This is an increase of 558% compared to the average volume of 1,008 put options.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Benchmark reissued a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. Wells Fargo & Company lifted their price target on shares of Heartflow from $39.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, November 13th. Stifel Nicolaus upped their price objective on Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, November 13th. Robert W. Baird boosted their price target on shares of Heartflow from $56.00 to $68.00 and gave the stock an “outperform” rating in a research report on Friday, November 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $64.00 price target (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.12.

Get Our Latest Stock Analysis on Heartflow

Heartflow Stock Performance

Shares of NASDAQ HTFL opened at $46.69 on Friday. The stock has a market cap of $4.10 billion, a PE ratio of -50.75 and a beta of 2.50. Heartflow has a 52-week low of $20.13 and a 52-week high of $60.65. The business has a fifty day moving average of $51.76 and a two-hundred day moving average of $35.64.

Heartflow (NASDAQ:HTFL – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 20.53% and a negative net margin of 33.11%. The firm had revenue of $72.86 million during the quarter. During the same quarter in the previous year, the firm posted ($0.27) EPS. Analysts predict that Heartflow will post -0.75 earnings per share for the current year.

More Heartflow News

Investors following HTFL have been watching these news items:

  • Positive Sentiment: A report headline says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially signaling stronger growth expectations. The provided article text offers few details on the results. Article: HeartFlow Q2 revenue and guidance
  • Negative Sentiment: Recent coverage flagged insider share sales, including a transaction reported at about $4.2 million. Other reports describe Campbell Rogers’ sales, some made under pre-arranged Rule 10b5-1 plans. Insider selling can unsettle investors, although planned sales do not necessarily signal a change in the insider’s view of the company. Article: Heartflow insider sale
  • Negative Sentiment: Put-option trading rose sharply, with 6,628 puts traded—about 558% above the reported average. This may reflect increased demand for downside protection or bearish bets, though options activity alone does not establish investors’ outlook.

Insiders Place Their Bets

In related news, insider Campbell Rogers sold 24,188 shares of Heartflow stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $46.39, for a total value of $1,122,081.32. Following the completion of the transaction, the insider owned 64,424 shares in the company, valued at approximately $2,988,629.36. The trade was a 27.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $55.74, for a total transaction of $2,168,286.00. Following the sale, the chief executive officer directly owned 251,983 shares of the company’s stock, valued at approximately $14,045,532.42. This trade represents a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 323,936 shares of company stock worth $16,355,191. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HTFL. GAMMA Investing LLC grew its position in Heartflow by 75.1% during the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after purchasing an additional 275 shares during the last quarter. IFP Advisors Inc grew its stake in Heartflow by 844.7% during the third quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after acquiring an additional 718 shares in the last quarter. Allworth Financial LP boosted its stake in Heartflow by 56.5% during the third quarter. Allworth Financial LP now owns 828 shares of the company’s stock valued at $41,000 after buying an additional 299 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Heartflow in the second quarter valued at $53,000. Finally, Essential Partners LLC bought a new stake in shares of Heartflow in the 1st quarter worth about $57,000.

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Featured Articles

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.